Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top London based VP’ operating in the Pharmaceutical space. If you think a VP’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Bruno Angelici
Executive VP of AstraZeneca
Bruno Angelici was appointed in 2007, current term until 2019. He was formerly Executive Vice President, Europe, Japan, Asia Pacific, Latin America, Middle East, and Africa of AstraZeneca Plc.
Follow Bruno Angelici:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Jeanne Bolger
Vice President Venture Investing of Johnson & Johnson Development Corporation
Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Follow Jeanne Bolger:
About Johnson & Johnson Development Corporation, Pulmocide: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Anthony Chow
VP IR of Juvenescence
Anthony Chow is a CFA Charter holder with broad experience as an investor. He commenced his career at ANZ Banking Group Ltd in Sydney, Australia where he worked as an analyst for four years in the corporate banking, leveraged finance and private equity teams. In 2007, Anthony moved to London to work for Jim Mellon at Burnbrae Group and Regent Pacific. Since joining, he was responsible research, direct investments, portfolio construction, risk management and facilitating trades in a wide range of financial instruments. He has worked closely with portfolio companies and respective coinvestors. He is currently the CEO of Burnbrae’s subsidiary Mann Bioinvest Limited and consultant to Juvenescence. He also sits on the board of The Diabetic Boot Company Limited, a medical device company. Anthony holds a Bachelor of Economics and Finance from The University of Sydney and a Post Graduate Diploma in Accounting from Macquarie University. He was awarded the CFA designation in 2010.
Follow Anthony Chow:
About Agronomics, Juvenescence: Juvenescence is a biotech company that develops therapies and products to modify aging and help people live longer.
Martin Lachs
Vice President Global Project Management of ICON plc
Follow Martin Lachs:
About ICON plc: ICON is a global provider of outsourced drug development services to biopharma, medical device, biosimilar and generic organizations.
Zeshan Ghory
VP of Operations & Analytics of Antidote.me
Follow Zeshan Ghory:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Simon Ashworth
VP, Head Safety and Pharmacovigilance of Autolus
Follow Simon Ashworth:
About Autolus, Takeda: Autolus is in T-cell programming and manufacturing technology.
Christopher Vann
Senior Vice President, Chief Operating Officer of Autolus
Christopher Vann leads commercial activities for Autolus. An industry veteran with 30 years’ experience in both development and business roles, he joined Autolus from Hoffmann-La Roche’s Swiss headquarters, where he was latterly responsible for leading the lung cancer commercial team and general management of the Tarceva brand. He has extensive experience of global lifecycle management of oncology products as well as implementing marketing strategy at a regional and national level. This includes launching several oncology, immunology and transplant products in countries such as China, Japan, Romania, Russia, South Africa, the UK and the USA. He gained his degree in toxicology and pharmacology from the School of Pharmacy, University of London.
Follow Christopher Vann:
About Autolus: Autolus is in T-cell programming and manufacturing technology.
Nicholas Lakin
Vice President, Advisory Services of Kinapse
Follow Nicholas Lakin:
About Kinapse: Kinapse provides advisory, capability building and operational services to the life sciences industries.
